Literature DB >> 21938443

Antitumor bifunctional dinuclear Pt(II) complex BBR3535 forms interduplex DNA cross-links under molecular crowding conditions.

Tereza Muchova1, Susana M Quintal, Nicholas P Farrell, Viktor Brabec, Jana Kasparkova.   

Abstract

When antitumor platinum drugs react with DNA they form various types of intrastrand and interstrand cross-links (CLs). One class of new antitumor platinum compounds comprises bifunctional Pt(II) compounds based on the dinuclear or trinuclear geometry of leaving ligands. It has been shown that the DNA-binding modes of dinuclear or trinuclear bifunctional Pt(II) agents are distinct from those of mononuclear cisplatin, forming markedly more intramolecular interstrand CLs. However, at least two types of DNA interstrand cross-linking by bifunctional Pt(II) complexes can be envisaged, depending on whether the platinum complex coordinates to the bases in one DNA molecule (intramolecular interstrand CLs) or in two different DNA duplexes (interduplex CLs). We hypothesized that at least some antitumor bifunctional poly(di/tri)nuclear complexes could fulfill the requirements placed on interduplex DNA cross-linkers. To test this hypothesis we studied the interduplex cross-linking capability of a representative of antitumor polynuclear agents, namely, dinuclear Pt(II) complex [{trans-PtCl(NH(3))(2)}(2)-μ-{trans-(H(2)N(CH(2))(6)NH(2)(CH(2))(2)NH(2)(CH(2))(6)NH(2))}](4+) (BBR3535). The investigations were conducted under molecular crowding conditions mimicking environmental conditions in the cellular nucleus, namely, in medium containing ethanol, which is a commonly used crowding agent. We found with the aid of native agarose gel electrophoresis that the DNA interduplex cross-linking efficiency of BBR3535 under molecular crowding conditions was remarkable: the frequency of these CLs was 54%. In contrast, the interduplex cross-linking efficiency of mononuclear cisplatin or transplatin was markedly lower (approximately 40-fold or 18-fold, respectively). We suggest that the production of interduplex CLs in addition to other DNA intramolecular adducts may provide polynuclear Pt(II) compounds with a wider spectrum of cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21938443     DOI: 10.1007/s00775-011-0845-0

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  30 in total

1.  Cell biology: join the crowd.

Authors:  R John Ellis; Allen P Minton
Journal:  Nature       Date:  2003-09-04       Impact factor: 49.962

2.  Bisintercalators of DNA with a rigid linker in an extended configuration.

Authors:  S T Mullins; N K Annan; P R Cook; G Lowe
Journal:  Biochemistry       Date:  1992-01-28       Impact factor: 3.162

3.  Sequence-dependent conformational changes in DNA induced by polynuclear platinum complexes.

Authors:  T D McGregor; Z Balcarová; Y Qu; M C Tran; R Zaludová; V Brabec; N Farrell
Journal:  J Inorg Biochem       Date:  1999-10       Impact factor: 4.155

4.  DNA modified by platinum derivatives cannot adopt the A-form.

Authors:  Z Balcarová; V Brabec
Journal:  Biochim Biophys Acta       Date:  1986-05-27

Review 5.  Cellular processing of platinum anticancer drugs.

Authors:  Dong Wang; Stephen J Lippard
Journal:  Nat Rev Drug Discov       Date:  2005-04       Impact factor: 84.694

6.  DNA modifications by a novel bifunctional trinuclear platinum phase I anticancer agent.

Authors:  V Brabec; J Kaspárková; O Vrána; O Nováková; J W Cox; Y Qu; N Farrell
Journal:  Biochemistry       Date:  1999-05-25       Impact factor: 3.162

7.  Different features of the DNA binding mode of antitumor cis-amminedichlorido(cyclohexylamine)platinum(II) (JM118) and cisplatin in vitro.

Authors:  Hana Kostrhunova; Oldrich Vrana; Tereza Suchankova; Dan Gibson; Jana Kasparkova; Viktor Brabec
Journal:  Chem Res Toxicol       Date:  2010-10-12       Impact factor: 3.739

8.  A comparison of DNA binding profiles of dinuclear platinum compounds with polyamine linkers and the trinuclear platinum phase II clinical agent BBR3464.

Authors:  Tracey D McGregor; Alexander Hegmans; Jana Kaspárková; Kamila Neplechová; Olga Nováková; Hana Penazová; Oldrich Vrána; Viktor Brabec; Nicholas Farrell
Journal:  J Biol Inorg Chem       Date:  2002-01-08       Impact factor: 3.358

Review 9.  The resurgence of platinum-based cancer chemotherapy.

Authors:  Lloyd Kelland
Journal:  Nat Rev Cancer       Date:  2007-07-12       Impact factor: 60.716

10.  Arrangements of human telomere DNA quadruplex in physiologically relevant K+ solutions.

Authors:  D Renciuk; I Kejnovská; P Skoláková; K Bednárová; J Motlová; M Vorlícková
Journal:  Nucleic Acids Res       Date:  2009-08-28       Impact factor: 16.971

View more
  2 in total

1.  Cytotoxic efficacy of a novel dinuclear platinum(II) complex used with anti-MUC1 in human breast cancer cells.

Authors:  Agnieszka Gornowicz; Zbigniew Kałuża; Anna Bielawska; Halina Gabryel-Porowska; Robert Czarnomysy; Krzysztof Bielawski
Journal:  Mol Cell Biochem       Date:  2014-03-18       Impact factor: 3.396

2.  Characterisation of the DNA sequence specificity, cellular toxicity and cross-linking properties of novel bispyridine-based dinuclear platinum complexes.

Authors:  Ben W Johnson; Vincent Murray; Mark D Temple
Journal:  BMC Cancer       Date:  2016-05-25       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.